2.05
Alector Inc (ALEC) 最新ニュース
Alector, Inc. (NASDAQ:ALEC) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Industry Analysts Just Upgraded Their Alector, Inc. (NASDAQ:ALEC) Revenue Forecasts By 60% - simplywall.st
HC Wainwright Issues Negative Outlook for Alector Earnings - MarketBeat
BofA Securities Maintains Alector(ALEC.US) With Sell Rating, Announces Target Price $1 - Moomoo
Bank of America Securities Sticks to Its Sell Rating for Alector (ALEC) - The Globe and Mail
H.C. Wainwright Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $5 - moomoo.com
Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Genmab (GMAB) and Xenon (XENE) - The Globe and Mail
TD Cowen Maintains Alector(ALEC.US) With Hold Rating - Moomoo
Alector Inc (ALEC) Stock News Today - TradingKey
Alector Inc (ALEC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alector earnings beat by $0.02, revenue topped estimates - Investing.com Canada
Alector (NASDAQ:ALEC) Releases Earnings Results, Beats Expectations By $0.02 EPS - marketbeat.com
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Alector, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Alector: Q2 Earnings Snapshot - Barchart.com
Alector, Inc. 2Q 2026: Revenue $3.32M, EPS $(0.21) — 10-Q Summary - TradingView
Alector | 10-Q: Q2 2026 Earnings Report - Moomoo
Alector (NASDAQ: ALEC) details Q2 loss, GSK exit and ABC pipeline focus - Stock Titan
Alector, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Alector reports Q2 2026: $172.8M cash; Q2 net loss $23.0M - TradingView
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Alector : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Primer: Alector Inc (ALEC US)Aug 2026 - Smartkarma
Alector Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Enterprise value to EBITDA forward of Alector, Inc. – NASDAQ:ALEC - TradingView
Alector (ALEC) Expected to Post Quarterly Earnings on Thursday - MarketBeat
Alector Inc (ALEC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alector Inc (ALEC) Institutional Confidence - TradingKey
Alector Inc (ALEC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alector (ALEC) Rises 2% as Stock Holds Above Key SupportTime Weighted Price - dars.gov.et
Alector Inc (ALEC) Balance Sheet - TradingKey
Alector Inc (ALEC) Cash Flow - TradingKey
Alector Inc (ALEC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALEC|Alector Inc|Price:1.480|Chg%:-0.010 - TradingKey
Alector Inc (ALEC) Income Statement - TradingKey
Alector Inc (ALEC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ALEC|Alector Inc|Price:1.510|Chg%:-0.110 - tradingkey.com
Spruce Street Capital LP Buys 983,082 Shares of Alector, Inc. $ALEC - MarketBeat
Alector, Inc. Revenue Breakdown – NASDAQ:ALEC - TradingView
Alector (ALEC) Hovers Near Support Amid Modest DeclineBollinger Band - dars.gov.et
Alector (ALEC) Goldman Sachs 45th Annual Global Healthcare Conference Summary - Quartr
Alector (ALEC) Proxy filing Summary - Quartr
Alector Q1 2026 Earnings: Narrower Loss Surprises, Yet Shares Dip Amid Revenue AbsenceCapex Guidance - DonanımHaber
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - Sahm
GSK exits Alector neurodegeneration alliance after trial failures - The Pharma Letter
Form 4 Alector Inc For: 9 July By Investing.com - Investing.com Nigeria
Alector (ALEC) awards 20,000 RSUs to principal accounting officer - Stock Titan
GSK ends brain drug alliance with Alector - BioPharma Dive
GSK Bids Farewell To Alector Dementia Deal - insights.citeline.com
GSK Walks Away From AlectorPipeline Reset Story Begins (NASDAQ:ALEC) - Seeking Alpha
GSK Terminates Neuroscience Collaboration with Alector Following Drug Trial SetbacksEPS Surprise History - dars.gov.et
Alector (ALEC) Shares Drop 13% Following Termination of GSK Coll - GuruFocus
Alector stock plummets 13% as GSK terminates neuroscience pact (GSK:NYSE) - Seeking Alpha
Alector and GSK partnership to end after dementia, Alzheimer’s drug failures - whbl.com
Alector, Inc. Terminates Material Definitive Agreement – Key 8-K Filing Update July 2026 - Minichart
Alector and GSK partnership to end after dementia, Alzheimer's drug failures - Reuters
Alector Ends GSK Collaboration, Retires Hercules Capital Debt - TipRanks
Alector to End GSK Progranulin Collaboration; Repays $10.4 Million Hercules Loan - TradingView
Alector (ALEC) sees GSK end antibody collaboration while repaying $10.4M loan - Stock Titan
大文字化:
|
ボリューム (24 時間):